Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 9/20 | 0.42 |
| ▸ | CA1 | P00915 | 8/20 | 0.42 |
| ▸ | CA9 | Q16790 | 7/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 4/20 | 0.41 |
| ▸ | CA7 | P43166 | 4/20 | 0.41 |
| ▸ | CA4 | P22748 | 3/20 | 0.41 |
| ▸ | CA6 | P23280 | 3/20 | 0.41 |
| ▸ | CA5A | P35218 | 3/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.39 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.39 |
| ▸ | CA3 | P07451 | 2/20 | 0.37 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5153721 | 0.84 | MAPK1 (0.46) | CA2CA1CA9CNR2CA12 | |
| SCHEMBL118621 | 0.83 | MAPT (0.45) | CA2CA1CA9CA12CA7 | |
| SCHEMBL5805029 | 0.83 | CA2 (0.61) | CA2CA1CA9CA12CA7 | |
| SCHEMBL3194901 | 0.82 | CA2 (0.43) | CA2CA1CA9CA12CA7 | |
| SCHEMBL11373202 | 0.81 | CNR2 (0.43) | CA2CA1CA9CNR2CA12 | |
| SCHEMBL3591889 | 0.81 | LMNA (0.55) | CA2CA1CA9CNR2ALDH1A1 | |
| SCHEMBL18316 | 0.79 | APEX1 (0.50) | CA2CA1CA9CA12CA7 | |
| Hydrochloric Acid SCHEMBL28120807 | 0.79 | CNR2 (0.42) | CA2CA1CA9CNR2CA12 | |
| SCHEMBL5358399 | 0.78 | ALDH1A1 (0.61) | CA2CA1CA9CNR2CA12 | |
| SCHEMBL11843973 | 0.78 | CA1 (0.39) | CA2CA1CA9CNR2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022096-A1 | NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS | GENECODE (EE) | 2026-01-22 | — | — | US | disclosed |
| EP-4561994-A1 | NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS | Genecode (EE) | 2025-06-04 | — | — | EP | disclosed |
| CN-119948015-A | Novel sulfonamides and their use as neuroprotective and/or nerve repair agents | 基因密码公司 | 2025-05-06 | — | — | CN | disclosed |
| US-12139497-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| EP-4448105-A1 | HETEROCYCLE DERIVATIVES FOR THE TREATMENT OF DISEASE | VIR Biotechnology, Inc. (US) | 2024-10-23 | — | — | EP | disclosed |
| EP-3466934-B1 | SULFONAMIDE COMPOUNDS OR SALT THEREOF AS RIBONUCLEOTIDE REDUCTASE INHIBITORS FOR TREATING CANCER | TAIHO PHARMACEUTICAL CO LTD (JP) | 2024-03-27 | — | — | EP | disclosed |
| WO-2024023284-A1 | NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS | GENECODE (EE) | 2024-02-01 | — | — | WO | disclosed |
| US-20230287005-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230287005-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230287005-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20170066783-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-09 | — | — | US | disclosed |
| US-20170066783-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-09 | — | — | US | disclosed |
| US-20170066783-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-09 | — | — | US | disclosed |
| WO-2017035353-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | WO | disclosed |
| EP-3134397-A1 | AMINO PYRAZINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | Novartis AG (CH) | 2017-03-01 | — | — | EP | disclosed |
| CN-106458979-A | Aminopyrazine derivatives as phosphatidylinositol 3-kinase inhibitors | 诺华股份有限公司 | 2017-02-22 | — | — | CN | disclosed |
| US-20170042889-A1 | AMINO PYRAZINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2017-02-16 | — | — | US | disclosed |
| WO-2015162459-A1 | AMINO PYRAZINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-10-29 | — | — | WO | disclosed |
| EP-0883613-A1 | SULFONAMIDE DERIVATIVES AS 5HT7 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1998-12-16 | — | — | EP | disclosed |
| WO-1997029097-A1 | SULFONAMIDE DERIVATIVES AS 5HT7 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1997-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066783-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Medical Disorders | CFD, F12, F3 | CA2 4275/4885CA1 4875/4885CA9 4629/4885 |
| US-20230287005-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, F12, F3 | CA2 4044/4885CA1 4856/4885CA9 4508/4885 |
| US-20260022096-A1 | NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS | CNR1, CDR2, SMN1; SMN2 | CA2 240/4885CA1 93/4885CA9 411/4885 |
| US-12139497-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | CFD, F12, F3 | CA2 4275/4885CA1 4875/4885CA9 4629/4885 |
| US-20170042889-A1 | AMINO PYRAZINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PI4KA, PIP5K1B, PIP4K2B | CA2 2489/4885CA1 3992/4885CA9 4825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.